Empagliflozin MAY attenuate adipose tissue inflammation and arterial stiffness in normotensive type 2 diabetics
Abstract
Objective: Adipose tissue inflammation impairs arterial compliance at early stages of type 2 diabetes mellitus (T2DM). We aimed to assess the impact of empagliflozin as compared to sitagliptin on aortic stiffness and serum adiponectin (ADPN), an adipocytokine with insulin-sensitizing, anti-inflammatory and anti-atherogenic properties, in normotensive patients with T2DM. Design and method: In this 24-week, randomized, open, parallel-group, controlled trial, 106 Caucasian normotensive T2DM subjects, inadequately controlled on metformin monotherapy (at least 1700 mg daily), were randomly assigned to receive 25 mg empagliflozin (n = 54) or 100 mg sitagliptin (n = 52) orally once daily. Arterial stiffness was assessed as carotid-femoral pulse wave velocity (PWV) measured via Complior (Artech Medical), whereas a sandwich enzyme-linked immunosorbent assay was employed for ADPN measurement. Office blood pressure (BP) was measured using a validated automated sphygmomanometer (Omron 705IT). Three measurements were taken at a 1-minute interval and were averaged for a single systolic/diastolic BP value. Results: In the entire study population, mean age was 50.4 years, diabetes duration 6.1 years, baseline HbA1c 7.7%, fasting plasma glucose [FPG] 159 mg/dl, body mass index 30.2 ± 4.1 kg/m2, systolic/diastolic BP 132.2/82.9 mmHg, glomerular filtration rate 89.9 mL/min/1.73m2, PWV 13.0 ± 2.1 m/s and ADPN 6.0 ± 1.8 &mgr;g/ml at baseline. After 24 weeks significant changes were observed in…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 54 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.